Spots Global Cancer Trial Database for gilteritinib
Every month we try and update this database with for gilteritinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | NCT02310321 | Acute Myeloid L... FLT3-mutated Ac... | gilteritinib Idarubicin Cytarabine | 18 Years - 69 Years | Astellas Pharma Inc | |
| Gilteritinib for the Treatment of ALK NSCLC | NCT06225427 | Lung Non-Small ... Stage IV Lung C... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Gilteritinib Magnetic Resona... Questionnaire A... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT03625505 | Acute Myeloid L... | Venetoclax Gilteritinib | 18 Years - | AbbVie | |
| A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | NCT02752035 | Acute Myeloid L... Acute Myeloid L... | gilteritinib azacitidine | 18 Years - | Astellas Pharma Inc | |
| Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | NCT03836209 | Acute Myeloid L... | Gilteritinib Midostaurin Daunorubicin Cytarabine | 18 Years - 70 Years | PrECOG, LLC. | |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | NCT05955261 | Acute Myeloid L... | Venetoclax Azacitidine Cytarabine Gemtuzumab Ozog... Daunorubicin Hy... Fludarabine Pho... Idarubicin Hydr... Mitoxantrone Hy... Etoposide Gilteritinib | 29 Days - 21 Years | St. Jude Children's Research Hospital | |
| Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02181660 | Acute Myeloid L... | Gilteritinib | 18 Years - | Astellas Pharma Inc | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | NCT03730012 | Acute Myeloid L... Acute Myeloid L... | gilteritinib atezolizumab | 18 Years - | Astellas Pharma Inc | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03409081 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | NCT04336982 | Leukemia, Myelo... | CC-90009 Venetoclax Azacitidine Gilteritinib | 18 Years - | Celgene | |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT03625505 | Acute Myeloid L... | Venetoclax Gilteritinib | 18 Years - | AbbVie | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | NCT03182244 | Acute Myeloid L... | gilteritinib LoDAC (Low Dose... MEC (Mitoxantro... FLAG (Granulocy... | 18 Years - | Astellas Pharma Inc | |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03070093 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02236013 | Acute Myeloid L... | Gilteritinib Idarubicin Cytarabine Daunorubicin | 18 Years - | Astellas Pharma Inc | |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | NCT06317649 | Acute Myeloid L... | Azacitidine Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Gilteritinib Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02495233 | Non-Small-Cell ... | Gilteritinib Erlotinib | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02495233 | Non-Small-Cell ... | Gilteritinib Erlotinib | 18 Years - | Astellas Pharma Inc | |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | NCT05955261 | Acute Myeloid L... | Venetoclax Azacitidine Cytarabine Gemtuzumab Ozog... Daunorubicin Hy... Fludarabine Pho... Idarubicin Hydr... Mitoxantrone Hy... Etoposide Gilteritinib | 29 Days - 21 Years | St. Jude Children's Research Hospital | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | NCT02997202 | Acute Myeloid L... | gilteritinib Placebo | 18 Years - | Astellas Pharma Inc | |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | NCT03182244 | Acute Myeloid L... | gilteritinib LoDAC (Low Dose... MEC (Mitoxantro... FLAG (Granulocy... | 18 Years - | Astellas Pharma Inc | |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | NCT02456883 | Advanced Solid ... Pharmacokinetic... | gilteritinib 14C-labeled gil... | 18 Years - | Astellas Pharma Inc | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | NCT03070093 | Acute Myeloid L... FMS-like Tyrosi... | gilteritinib | 18 Years - | Astellas Pharma Inc | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation | NCT04691648 | Acute Myeloid L... | Gilteritinib Ex... | 18 Years - | Astellas Pharma Inc | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | NCT04027309 | Acute Myeloid L... Myelodysplastic... | Gilteritinib Midostaurin | 18 Years - | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | NCT06317649 | Acute Myeloid L... | Azacitidine Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Gilteritinib Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05028751 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Lanraplenib Gilteritinib | 18 Years - | Kronos Bio |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
